U.S. FDA Issues Life Ban For 27 Ranbaxy Products, Company Says Move To Have “Negligible Commercial Impact”
This article was originally published in PharmAsia News
Executive Summary
A consent decree signed in January specified Ranbaxy must never submit another application for the withdrawn products.